Illuminating the Power of Collaborative Care in nAMD and DME: Advancing the Shift to Treatment Innovations

February 2, 2025

Countdown to Event

00

Days

00

Hours

00

Mins

00

Secs

Overview:

Although anti-VEGF therapies have advanced the management of nAMD and DME, limitations with their use – including the need for frequent injections and incomplete response for many patients – led to the development of newer anti-VEGF agents. In this program, expert faculty will share opportunities to improve the diagnosis of nAMD and DME, educate patients on their treatment options, and participate in team-based care for these patients.


Learning Objectives:

Upon completion of this activity, participants will be able to:

  • Analyze the role of the optometrist in identifying and diagnosing nAMD
  • Summarize optometrists’ responsibility in identifying and diagnosing DME
  • Evaluate the impact of advanced therapies in the management of nAMD
  • Analyze the impact of managing DME with advanced treatments
  • Describe optimal strategies for collaborative multidisciplinary care and communication between optometrists and retina specialists